Canopy Growth: Penny Stock Rebound or Dilution Trap?

Canopy Growth is showing signs of a business rebound, reporting a 13% year-over-year revenue increase in the first fiscal quarter of 2027. This growth was broad-based, with its Canadian medical marijuana business up 22%, Canadian adult-use up 10%, international cannabis up 10%, and the Storz & Bickel division up 6%.

This improvement follows a strategic recapitalization in early 2026, which reduced debt by issuing equity. The company also acquired MTL Cannabis in an all-stock deal. These actions, while strengthening the balance sheet, significantly diluted existing shareholders, increasing the share count by over 25% in the last year and over 400% in three years.

Despite the operational gains, Canopy Growth's stock has traded in penny-stock territory since mid-2025, signaling a high-risk investment profile. Most investors are advised against purchasing the stock, even with the recent positive quarterly results.